Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Reshuffles Top Management

North America Commercial Head Brendan O’Grady Moves On

Executive Summary

Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.

You may also be interested in...



Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?

Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.

What’s Next? Five Things To Look Out For In August

In the month ahead, Teva will see a key management change, Polpharma is set to wrap up a landmark Phase III biosimilar study and financial results for all manner of industry participants will continue to trickle out.

Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance

Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel